eXoZymes Reports Q3 Net Loss, Selects Curia

The biomanufacturing company posted a third-quarter 2026 net loss of $2.24 million and named Curia as its commercial-scale manufacturing partner.

Updated on Nov. 19, 2026 in Public Companies

Brushed stainless-steel bioreactor vessels and coiled piping in a light-industrial bay, with dry golden hills visible through an open door.
eXoZymes reported a third-quarter 2026 net loss of $2.24 million and named Curia as its commercial-scale manufacturing partner for its lead ingredient. AI Illustration. Upload story photo >

eXoZymes Inc. reported third-quarter 2026 results on November 19, 2026, showing a net loss of $2.24 million for the quarter. The company also said it selected Curia as its commercial-scale manufacturing partner for NCT in September 2026.

Why it matters

The results show the company's operating costs and cash position as it moves a lead ingredient toward larger-scale production. Investors and readers tracking early-stage biomanufacturers can use the figures to gauge spending and funding needs.

Operating expenses rose to $3.05 million in the third quarter of 2026 from $2.52 million a year earlier, and the quarter's $2.24 million net loss included a $0.77 million non-cash warrant gain. Cash and equivalents stood at $3.26 million at quarter end, and the release does not say how the Curia manufacturing work will affect future expenses.

The players

eXoZymes Inc.

eXoZymes is a biomanufacturing company that uses a cell-free platform built around AI-enhanced enzymes it calls exozymes, and it is publicly traded.

The details

eXoZymes said it advanced Product AMETHYST through proof of concept and began scale-up activities for Product SAPPHIRE. The company introduced Tyferyn as the new brand name for its lead nutraceutical ingredient, and technology transfer to Curia began in the fourth quarter of 2026.

Timeline

  1. September 2026: eXoZymes selected Curia as its NCT commercial manufacturing partner.

  2. September 30, 2026: The third quarter of 2026 ended.

  3. Fourth quarter 2026: Technology transfer to Curia began.

  4. November 19, 2026: Third-quarter results were reported and an investor webinar was held.

  5. Beginning of 2027: Current cash is expected to support operations through this point.

Market Landscape

The Curia selection is a step toward commercial scale for eXoZymes' cell-free exozyme platform, a method that differs from conventional fermentation-based ingredient production. Whether the approach can compete on cost at scale remains the central question for companies in this niche.

For readers following the stock or the ingredient, the reported cash of $3.26 million and expected runway into early 2027 signal that additional financing may be needed. The Tyferyn brand name is the consumer-facing product to watch for in the nutraceutical market.

The takeaway

Investors should compare the rising operating expenses and limited cash against the Curia manufacturing timeline. The 2027 scale-up plans will determine whether the company can extend its runway.

Further reading

Track more company earnings in the Public Companies section.

More information

Watch the eXoZymes investor webinar recording and update for management's full third-quarter discussion.

Source note: This article includes information reported by Hawaii Telegraph.